Broadfin Capital Initiates Stake in Pernix Therapeutics (PTX)
Last night, Broadfin Capital, a healthcare focused hedge fund managed by Kevin Kotler, disclosed in a Securities and Exchange Commission filing that it has initiated a 3.5 million...
Posts Tagged ‘Kevin Kotler’
Kevin Kotler’s Broadfin Capital Reports New Stake In MELA Sciences Inc (MELA)
Kevin Kotler’s Broadfin Capital, in its latest filing with the Securities and Exchange Commission, has reported ownership of 9.09 million shares of MELA Sciences Inc (NASDAQ...
Kevin Kotler’s Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO
Broadfin Capital, led by Kevin Kotler, in a filing with the Securities and Exchange Commission, reported initiating a position in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO).
Steven Cohen Also Initiates Stake in Retrophin Inc (RTRX)
Steven Cohen, in a new filing with the SEC disclosed initiating a stake in Retrophin Inc (NASDAQ:RTRX). According to the filing, Mr.
Broadfin Capital Initiates a Stake in Retrophin Inc (RTRX) Following Its Listing on NASDAQ
Kevin Kotler’s Broadfin Capital has revealed a new stake in Retrophin Inc (NASDAQ:RTRX), which amasses 6.93% of the company’s common stock, it contains 1.61 million shares...
Broadfin Capital Ups Position in Rigel Pharmaceuticals, Inc. (RIGL)
Kevin Kotler's Broadfin Capital increased its exposure to Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a filing with the SEC showed.
Deerfield Management Initiates Passive Stake in Horizon Pharma Inc (HZNP)
James E. Flynn's healthcare-focused Deerfield Management has revealed, in a new filing with the SEC, initiating a passive stake in Horizon Pharma Inc (NASDAQ:HZNP).
Kevin Kotler, Broadfin Capital Raise Holding in Derma Sciences Inc (DSCI)
Kevin Kotler's Broadfin Capital has increased its position in Derma Sciences Inc (NASDAQ:DSCI).
Broadfin Capital Boosts Stake in Horizon Pharma, Adds Alliqua to Its Equity Portfolio
In two newly amended filings with the SEC, Kevin Kotler's Broadfin Capital disclosed moves into Horizon Pharma Inc (NASDAQ:HZNP), and Alliqua Inc (OTCMKTS:ALQAD).
How One Anacor Pharmaceuticals Insider is Making Bank
Anacor Pharmaceuticals, Geoffrey Parker: In a recent Form 4 filing with the SEC, M.
Broadfin Capital Opens a Stake in Celsus, Another Biotech Company Today
Broadfin Capital, Celsus: Broadfin Capital, managed by Kevin Kotler, just disclosed a position in Celsus Therapeutics (OTCQB: CLSXY).
Kevin Kotler’s Broadfin Capital Joins HealthCor in Idera
Broadfin Capital, Idera Pharmaceuticals: Just now, Kevin Kotler's Broadfin Capital disclosed adding Idera Pharmaceuticals Inc (NASDAQ:IDRA) to its equity portfolio in a filing...
Broadfin Capital Thinks CAS Medical Systems Inc (CASM) Is Worth Some Cash
Even though passive "hedgies" do not benefit from the same amount of coverage as their activist peers, their moves should also be watched closely.
Progenics Pharmaceuticals, Inc. (PGNX): Insiders Aren’t Crazy About It But Hedge Funds Love It
To the average investor, there are tons of indicators shareholders can use to watch publicly traded companies.
Hedge Funds Are Selling BioDelivery Sciences International, Inc. (BDSI)
At the moment, there are many indicators market participants can use to watch their holdings. Two of the most under-the-radar are hedge fund and insider trading activity.
Should You Avoid Insulet Corporation (PODD)?
To many of your peers, hedge funds are assumed to be delayed, outdated financial tools of a period lost to current times.
Do Hedge Funds and Insiders Love Integra Lifesciences Holdings Corp (IART)?
If you were to ask many market players, hedge funds are viewed as useless, old investment vehicles of an era lost to time.
Masimo Corporation (MASI): Are Hedge Funds Right About This Stock?
At the moment, there are plenty of gauges market participants can use to monitor publicly traded companies.
Hedge Funds Aren’t Crazy About Cutera, Inc. (CUTR) Anymore
Now, according to many traders, hedge funds are perceived as useless, old investment vehicles of a period lost to current times.
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
In the eyes of many investors, hedge funds are viewed as overrated, old investment vehicles of an era lost to time.
Robotic Surgery News: Intuitive Surgical, Inc. (ISRG)’s Market Saturation, MAKO Surgical Corp. (MAKO)’s Traders
Intuitive Surgical makes surgical robots. In early 2009, during the panic, it dropped briefly below $90 per share.
Hedge Funds Are Crazy About Alkermes Plc (ALKS)
In the financial world, there are plenty of indicators shareholders can use to watch stocks. A couple of the best are hedge fund and insider trading activity.
Hedge Funds Are Buying Impax Laboratories Inc (IPXL)
At the moment, there are tons of indicators shareholders can use to analyze publicly traded companies.
Depomed Inc (DEPO): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?
In the eyes of many market players, hedge funds are viewed as delayed, outdated financial vehicles of an era lost to time.
Hi-Tech Pharmacal Co. (HITK): Hedge Funds Aren’t Crazy About It, Insider Sentiment Unchanged
To the average investor, there are tons of gauges investors can use to monitor stocks. A duo of the best are hedge fund and insider trading activity.
Merit Medical Systems, Inc. (MMSI): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?
In the 21st century investor’s toolkit, there are a multitude of methods shareholders can use to track Mr. Market.
Hedge Funds Are Selling MAKO Surgical Corp. (MAKO)
In today’s marketplace, there are many gauges market participants can use to track publicly traded companies.
Natus Medical Inc (BABY): Are Hedge Funds Right About This Stock?
If you were to ask many of your fellow readers, hedge funds are seen as useless, outdated financial vehicles of a period lost to current times.
Hedge Funds Aren’t Crazy About Rigel Pharmaceuticals, Inc. (RIGL) Anymore
In the eyes of many investors, hedge funds are seen as useless, outdated investment tools of a forgotten age.
Hedge Funds Are Selling Emergent Biosolutions Inc (EBS)
To many investors, hedge funds are viewed as delayed, outdated financial vehicles of a forgotten age.
NPS Pharmaceuticals, Inc. (NPSP): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In today’s marketplace, there are tons of gauges market participants can use to track their holdings.
Do Hedge Funds and Insiders Love Alere Inc (ALR)?
Now, according to many market players, hedge funds are assumed to be bloated, old investment tools of a period lost to current times.
This Metric Says You Are Smart to Sell Derma Sciences Inc (DSCI)
Derma Sciences Inc (NASDAQ:DSCI) was in 7 hedge funds' portfolio at the end of the first quarter of 2013. DSCI has seen a decrease in enthusiasm from smart money lately.
Hedge Funds Are Buying Solta Medical Inc (SLTM)
Is Solta Medical Inc (NASDAQ:SLTM) worth your attention right now? Investors who are in the know are getting more bullish.
DURECT Corporation (DRRX): Hedge Funds and Insiders Are Bullish, What Should You Do?
To most stock holders, hedge funds are assumed to be underperforming, outdated financial vehicles of years past.
AtriCure Inc. (ATRC): Are Hedge Funds Right About This Stock?
In today’s marketplace, there are tons of indicators market participants can use to monitor the equity markets.
Hedge Funds Are Betting On Globus Medical Inc (GMED)
In the eyes of most traders, hedge funds are seen as slow, old financial vehicles of years past.
Is Novadaq Technologies Inc. (NVDQ) Going to Burn These Hedge Funds?
In the financial world, there are a multitude of gauges market participants can use to track their holdings. A couple of the best are hedge fund and insider trading sentiment.
Should You Buy Insulet Corporation (PODD)?
Insulet Corporation (NASDAQ:PODD) was in 14 hedge funds' portfolio at the end of the first quarter of 2013.
Here is What Hedge Funds Think About Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) was in 11 hedge funds' portfolio at the end of March. INSM shareholders have witnessed an increase in enthusiasm from smart money of late.
